EU/3/19/2221

About

On 13 November 2019, orphan designation EU/3/19/2221 was granted by the European Commission to Monopar Therapeutics S.A.R.L, France, for camsirubicin for the treatment of soft tissue sarcoma.

Key facts

Active substance
Camsirubicin
Disease / condition
Treatment of soft tissue sarcoma
Date of first decision
13/11/2019
Outcome
Positive
EU designation number
EU/3/19/2221

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product it it is approved for marketing authorisation.

Sponsor's contact details

Monopar Therapeutics SARL
12 rue Anselme
93400 Saint-Ouen
France
Tel: +33 7 6702 4099
E-mail: robinson@monopartx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating